Shares of Monopar Therapeutics (MNPR) surged 8.74% during intraday trading on Tuesday, following a bullish report from JonesTrading analyst Soumit Roy. The analyst maintained a "Buy" rating on the stock and set an impressive price target of $130.00, signaling strong confidence in the company's future prospects.

Roy's optimistic outlook appears to be driven by promising data from Monopar's ALXN1840 drug candidate and the company's robust financial position. While specific details of the ALXN1840 data were not disclosed, the positive sentiment suggests potential advancements in Monopar's drug development pipeline, which could significantly impact the company's growth trajectory.

The substantial price target of $130.00 implies considerable upside potential for Monopar Therapeutics' stock, attracting investor attention and likely contributing to today's sharp price increase. As the biotech sector continues to garner interest from both institutional and retail investors, Monopar's strong analyst backing and promising drug candidates position the company as an attractive investment opportunity in the evolving healthcare landscape.